Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced (Stage IIIb not amenable for combined modality treatment), metastatic (Stage IV) or recurrent non-squamous non-small cell lung cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Adequate hematological, renal and liver function~Exclusion Criteria:~* Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of the disease (Stage IIIb, IV or recurrent disease)~* Mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component~* Evidence of tumor invading major blood vessels on imaging~* Central nervous system (CNS) metastases, even if previously treated~* History of hemoptysis in the 3 months prior to enrollment~* History or evidence of inherited bleeding diathesis or coagulopathy~* Uncontrolled hypertension and/or history of hypertensive crisis or hypertensive encephalopathy~* Clinically significant cardiovascular or vascular disease~* Malignancies other than non-small cell lung cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or localized prostate cancer or ductal carcinoma in situ treated surgically with curative intent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + Paclitaxel/Carboplatin (Type: EXPERIMENTAL): Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
- Placebo + Paclitaxel/Carboplatin (Type: ACTIVE_COMPARATOR): Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).